Posted by Michael Wonder on 09 May 2024
Health Canada approves Zoladex LA for the management of oestrogen receptor positive early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and peri-menopausal women
7 May 2024 - TerSera Canada today announced that Health Canada has approved a supplemental new drug submission for Zoladex LA (goserelin acetate) 10.8 mg every 12 weeks for the management of oestrogen receptor positive early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and peri-menopausal women.
While the monthly dose of Zoladex (3.6 mg) has been approved for use in breast cancer since 1995, this recent approval provides a 3 month dosing option for young women with hormone positive breast cancer.
